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1 Equal contribution.Protein adapters couple surface receptors to multiple intracellular signaling modules by acting as
scaffolds for the assembly of multimolecular complexes responsible for the coordination and ampli-
ﬁcation of signals. Through the spatiotemporally controlled recruitment of mediators with opposite
activities (e.g. protein tyrosine kinases and phosphatases), adapters are implicated not only in signal
initiation and propagation, but also in feedback loops for signal extinction. Moreover, adaptors spe-
cialized in preventing or dampening signaling have been more recently discovered. Here we shall
present of brief overview of the principal adaptors which act as negative regulators of TCR and
BCR signaling, with a focus of the mechanisms underlying this function. We shall then discuss
our recent ﬁndings implicating p66Shc and Rai, two members of the Shc family of cytosolic protein
adapters, in the negative control of antigen receptor signaling, and their role as gatekeepers of auto-
immunity and leukemia.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In the last decade molecular adapters have emerged as key par-
ticipants in immunoreceptor signaling. While not directly impli-
cated in the initiation of the signaling cascades triggered by
immunoreceptors, adapters provide the scaffolds required for the
activation, integration and ﬁne-tuning of multiple signaling mod-
ules, accounting for the complexity and plasticity of immunorecep-
tor signaling and for the strikingly diverse biological outputs.
Adapters have moreover been implicated in termination of signal-
ing through the temporally controlled recruitment of negative reg-
ulators, such as proteins and lipid phosphatases and ubiquitin
ligases, close the activated receptor. Accumulating evidence, ob-
tained principally in genetically manipulated mice, has more re-
cently underscored a previously unappreciated role of adapters in
dampening the signals triggered by immunoreceptors, thereby
preventing potentially dangerous pathological outcomes resulting
from uncontrolled lymphocyte hyperreactivity to both self and for-
eign antigen. This applies not only to ‘‘dedicated” adapters (e.g.
phosphoprotein associated with glycosphingolipid-enriched do-chemical Societies. Published by E
volutionary Biology, Via Aldomains, PAG), but also to adapters previously believed to only medi-
ate positive signals (e.g. non-T-cell activation linker, NTAL).
Here we shall summarize our present understanding of the
mechanisms of attenuation of T cell receptor (TCR) and B cell
receptor (BCR) signaling by molecular adapters and discuss the
pathological outcome of their deﬁciency, with a focus on our re-
cent ﬁndings implicating speciﬁc members of the Shc (Src
homology domain containing) family of protein adapters as neg-
ative regulators of antigen receptor signaling, autoimmunity and
cancer.
2. The role of protein adapters in the negative control of antigen
receptor signaling
Antigen receptor signaling is coordinately regulated by two
classes of adapters, grouped on the basis of their subcellular local-
ization. Cytosolic adapters essentially consist of an array of pro-
tein/protein and protein/lipid interaction domains and can
include one or more phosphorylatable tyrosine residues. At vari-
ance, transmembrane adapters lack the typical interaction do-
mains of their cytosolic counterparts. Rather, they are provided
of a long cytosolic tail which includes several tyrosine residues
which, when phosphorylated, become docking sites for proteins
provided of phosphotyrosine binding domains (Src Homology
2 domain, SH2, and phosphotyrosine-binding domain, PTB).
These adaptors form large scaffolds ideally suited for assemblinglsevier B.V. All rights reserved.
4916 N. Capitani et al. / FEBS Letters 584 (2010) 4915–4922multimolecular complexes, which in many instances include
cytosolic adaptors, thereby extending the combinatorial potentialTable 1
Negative regulatory adapters in TCR and BCR signaling.a
a Background colours highlight the classes of adapters described in Sections 2.1–2.3
signaling. Aminoacid residues refer to the human proteins.of the scaffold itself. Both classes of adapters include members
implicated in the negative control of antigen receptor signaling.. p66Shc and Rai are included among the adaptors dampening antigen receptor
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speciﬁcity and functions of the best characterized among these
adapters within the TCR and BCR signaling cascades (excluding
adapters with enzymatic functions) are summarized in Tables 1
and 2. For a detailed description we shall refer the reader to excel-
lent recent reviews.
2.1. Adaptors which prevent or attenuate signal initiation
Notwithstanding its capacity to interact with signaling media-
tors implicated in different steps of the TCR signaling cascade,
the principal function of the transmembrane adaptor PAG [1,2] is
to prevent initiation of antigen receptor signaling. PAG acts at
the onset of TCR signaling by controlling the activation of Lck,
the kinase that initiates TCR signaling by phosphorylating the
immunoreceptor tyrosine-based activation motifs (ITAMs) in the
cytosolic tails of the TCR/CD3 complex. In quiescent T cells PAG
is constitutively phosphorylated and associated with the kinase
Csk (c-src tyrosine kinase), which is responsible for maintaining
Lck (leukocyte-speciﬁc protein tyrosine kinase) in its close, inactive
conformation by phosphorylating the inhibitory C-terminal tyro-
sine residue, Y505. Since both PAG and Lck are segregated to lipid
rafts through their post-translationally added acyl moiety, PAG
prevents initiation of TCR signaling by positioning Csk in close
proximity to Lck. TCR engagement leads to a transient dephospho-
rylation of PAG, likely by CD45, which results in Csk release andTable 2
Immune related alterations in mice knockout for negative regulatory adapters.a
a Background colours highlight the classes of adapters described in Sections 2.1–2.3
signaling.Lck activation. A feedback loop triggered by the TCR involving
PAG phosphorylation by Fyn restores the basal state. PAG also con-
tributes to control the extent and duration of Ras activation by
recruiting RasGAP (Ras GTPase activating protein) to lipid rafts
and moreover limits raft motility by interacting with the actin
cytoskeleton. Strikingly, PAG/ mice do not have any obvious de-
fect either in lymphocyte development or activation, suggesting
the existence of compensatory mechanisms [3].
Abortive initiation of TCR signaling due to Csk recruitment to a
membrane-proximal position may also underlie the inhibitory
activity of the non-raft transmembrane adapter SIT (SHP2-
interacting transmembrane adaptor protein) [4]. Although SIT
can act as both positive and negative regulator of TCR signaling,
the latter function appears dominant, as underscored by the fact
that positive selection is converted to negative selection in TCR
transgenic SIT/ mice. In the periphery, SIT limits homeostatic T
cell proliferation [5]. Signaling is moreover enhanced in peripheral
T cells from SIT/ mice, and the peripheral T cell repertoire
appears skewed towards the T helper 1 (Th1) lineage, which is
likely to underlie their increased susceptibility to develop experi-
mental autoimmune encephalomyelitis (EAE) when immunized
with myelin oligodendrocyte glycoprotein [3,6]. SIT may therefore
be implicated in tuning the strength of the signals emanated from
the TCR.
A different mechanism underlies the inhibitory activity of the
Src-like adapter protein SLAP, which is prevalently associated to. p66Shc and Rai are included among the adaptors dampening antigen receptor
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SLAP can interact through its SH2 and SH3 domains with a number
of proximal components of the TCR and BCR signaling pathways,
including tyrosine phosphorylated TCRf and Iga, respectively,
which may dampen signaling by limiting access to ZAP-70 (Zeta-
chain-associated protein kinase 70) and Syk (Spleen tyrosine ki-
nase) on the activated receptors. The best characterized function
of SLAP is however to promote the degradation of recycling TCR
and BCR complexes through recruitment of the ubiquitin ligase
c-Cbl (Casitas B-lineage Lymphoma) and targeting of the ubiquiti-
nated receptors to lysosomes. Consistent with this function, double
positive thymocytes express higher levels of surface TCR, which in-
creases the efﬁciency of positive selection. Moreover immature B
cells have increased tonic BCR signaling, which correlates with
higher levels of surface BCR. Hence SLAP indirectly inﬂuences the
strength of antigen receptor signaling by modulating the levels of
surface receptor [9].
2.2. Adaptors which dampen antigen receptor signaling
A number of adapters modulate antigen receptor signaling at
different levels after its onset, i.e. downstream of ITAM phosphor-
ylation in the cytosolic tails of the CD3 and Iga/Igb complexes. As
predictable, targeting early components in the respective cascades
affects to a wider extent TCR and BCR signaling than targeting
more downstream components. Interestingly, in most instances
negative regulation by adapters occurs at the early steps in antigen
receptor signaling, suggesting that they may have evolved to tune
down these signaling cascades as a whole.
The transmembrane non-lipid raft-associated, LAT-related adap-
ter LAX (Linker for activation of X cells) [10] acts in concert with the
cytosolic adapter, ALX (Adaptor in Lymphocytes of unknown func-
tion X) [11], which promotes LAX phosphorylation by recruiting
Lck. LAX is phosphorylated in response to antigen receptor engage-
ment and in this state forms a complex with the cytosolic adapters
Grb2 (Growth factor receptor-bound protein 2) and Gads (Grb2-re-
lated adaptor downstreamof Shc), aswell aswith phosphatidil inos-
itol-3 kinase (PI-3K). It has been proposed that LAX acts a sink to
sequester these signaling mediators, thereby limiting their avail-
ability for interactionwith positive regulators. Although in cell lines
LAX appears to selectively inhibit p38 andAP-1 activation,which re-
sults in impaired IL-2 expression, LAX/ T andB cells harbour a gen-
eralized hyperreactivity to antigen receptor engagement, as shown
by enhanced protein tyrosine phosphorylation, Ca+2 mobilization,
and Akt and MAPK (Mitogen Activated Protein Kinase) activation,
suggesting that this adapter might be implicated in the regulation
of early signaling [12]. ALX/ lymphocytes display a similar pheno-
type, in agreement with the participation of LAX and AXL in a func-
tional complex [11]. Interestingly,mice doubly deﬁcient for LAX and
SIT display increased numbers of B-1 cells, hyperglobulinemia and
accumulation of CD4+ T cells in secondary lymphoid organs, indicat-
ing that LAX also cooperateswith SIT in dampening antigen receptor
signaling [3].
Initially discovered as the LAT (Linker of Activated T cells)
homologue in B cells, NTAL, also known as LAB (Linker of Activated
B cells) or LAT2, is actually widespread among immune cells,
including T cells, which upregulate its expression during activation
[13]. Consistent with its structural similarities with LAT, NTAL has
been implicated in the positive regulation of BCR signaling,
although the lack of B cell defects in NTAL/ mice indicates that
it may a play a limited role in B cells. Surprisingly, aged NTAL/
mice spontaneously a lupus-like autoimmune disease marked by
splenomegaly, presence of circulating anti-double stranded
(ds)DNA and anti-nuclear antibodies, and glomerular deposition
of immune complexes [14]. In these mice peripheral T cells are
hyperactivated, produce higher levels of cytokines and displaymore rebust proliferative responses to TCR engagement compared
to their wild-type counterparts. Moreover, a number of signaling
mediators are hyperactivated in response to TCR engagement in
NTAL/ T cells, including PLCc (Phospholipase Cc), Erk (Extracel-
lular signal regulated kinase) and Akt, indicating that NTAL damp-
ens an early step in TCR signaling and supporting the notion that
NTAL may play opposite roles depending on the cell context (T
vs B cell) [14]. Interestingly, despite its similarities to LAT, NTAL
lacks the tyrosine residue (Y136) responsible for the interaction
of LAT [15] with PLCc which, by promoting the development of
CD4+CD25+ regulatory T cell (Treg) cells, is implicated in suppres-
sion of CD4+ T cell activation. This unexpected inhibitory function
of LAT has been dramatically highlighted in knockin mice lacking
Y136, which develop a fatal Th2-driven lymphoproliferative
autoimmune disease characterized by hyperactivated T and B
cells, massive IgE and IgG1 production and severe tissue inﬁl-
tration that causes lymphoadenopathy and multiorgan damage
[16–18]. Hence, in addition to its well established function in
the positive regulation of TCR signaling, LAT also indirectly
suppresses signals driving T cell activation by promoting Treg
development.
At variance with the dual regulatory function of LAT and NTAL,
the Dok family of cytosolic adapters plays a univocal role in the
negative control of antigen receptor signaling [19]. All Dok (Down-
stream of tyrosine kinases) proteins share a highly conserved do-
main organization, with a N-terminal PH domain essential for
their recruitment to the membrane, a PTB domain and a C-terminal
tail which includes several phosphorylatable tyrosine residues and
proline-rich motifs. Dok proteins are therefore regulated by the
combined activity of protein tyrosine kinases and lipid kinases. Fol-
lowing their phosphorylation in response to antigen receptor
engagement, Dok-1 (expressed in both T and B cells) and Dok-2
(expressed in T cells) recruit p120RasGAP to a membrane-proximal
localization, thereby controlling the duration of Ras activation.
Consistent with this function, T cells from Dok-1/ and Dok-2/
mice show enhanced TCR-dependent IL-2 production and prolifer-
ation. Similarly, not only is Erk activation sustained in Dok-1/ B
cells, but these cells proliferate even when the inhibitory receptor
FccRIIB is coengaged with the BCR [21]. Of note, Dok-1/ and Dok-
2/ T cells also display enhanced activation of ZAP-70, possibly by
preventing its access to the phosphorylated CD3 ITAMs, indicating
that Dok proteins act at multiple steps in TCR signaling, beginning
from the earliest events [20]. Although no pathology is observed in
either Dok-1/ or Dok-2/ mice despite the hyperreactivity of T
cells to antigen receptor engagement, Dok-1/Dok-2/ mice dis-
play enhanced Ig responses to T-dependent antigens and, eventu-
ally, develop a spontaneous lupus-like autoimmune disorder
characterized by autoantibody production and diffuse proliferative
glomerulonephritis as a result of Ig-complement immune complex
deposition in the glomeruli [20], suggesting a functional redun-
dancy of these two adapters in vivo. Another member of the Dok
family, Dok-3, which is expressed in B cells and lacks the YXXP
motif responsible for p120RasGAP binding, is implicated in the
negative regulation of PLCc2 activation and Ca+2 mobilization, as
demonstrated in Dok-3/ B cells [22]. This activity involves
recruitment of Grb2, which prevents activation of the kinase Btk
through an as yet uncharacterized mechanism. Dok-3 interacts
moreover with the lipid phosphatase SHIP-1 (SH2-containing Inos-
itol Phosphatase-1) through its PTB domain, which results in the
selective inhibition of JNK (c-Jun N-terminal Kinase) activation
[23]. Recently Dok-4 has been shown to be expressed in T cells,
where it accumulates in an intracellular vesicular compartment
that is recruited to the polarized MTOC at the immunological syn-
apse. Similar to Dok-1 and Dok-2, Dok-4 antagonizes Erk activa-
tion, however the mechanism is different as it involves activation
of the Ras-like GTPase Rap1 [24].
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Adapters mediating positive signaling have the potential to
also generate feedback loops through the temporally controlled
recruitment of enzymes (e.g. protein tyrosine phosphatases, lipid
phosphatases) capable to reverse the events triggered by the
activated receptor. A striking example of this adapter-based
feedback circuitry is LAT, which acts as a potent positive regula-
tor of TCR signaling by providing a scaffold where the principal
signaling modules implicated in T cell activation are assembled
and coordinated [25]. Feedback control of TCR signaling by LAT
involves its interaction with two cytosolic adaptors, Gads and
Grb2, which also participate in positive signaling. Gads/Grb2
bind through their SH3 domains to another cytosolic adaptor,
Gab2 (Grb2 associated binder) [26]. This in turn recruits the
phosphatase SHP-2 (SH2 domain-containing phosphatase 2)
close to the plasma membrane, thereby positioning it in the
appropriate location to terminate TCR signaling by dephospho-
rylating key mediators, beginning from the CD3 ITAMs. Grb2 also
forms a complex with SHIP-1, which recruits Dok-2, resulting in
dampening of TCR signaling.
The transmembrane adaptor TRIM (TCR-Interacting Molecule)
[27] contributes to terminate TCR signaling through a different,
indirect mechanism. TRIM associates in the trans-Golgi network
with CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), a potent inhibi-
tor of TCR signaling which substitutes the costimulatory receptor
CD28 in the interaction with B-7 on the antigen presenting cell,
bringing the phosphatase SHP-1 close to the TCR. TRIM acts as a
molecular chaperone, facilitating the transport of CTLA-4 to the cell
surface, thereby indirectly suppressing TCR signaling [3,28].3. p66Shc and ShcC/Rai: novel players in the game
Recent evidence obtained in knockout mice has identiﬁed two
members of the Shc family of protein adapters, p66ShcA
(p66Shc) and p52ShcC/Rai (Rai) as novel mediators of negative sig-
naling in both T and B cells. The structure and principal features of
these adapters are presented in Tables 1 and 2, and the role in TCR
and BCR signaling is schematized in Fig. 1.
3.1. Expression, structure and function of p66Shc in lymphocytes
Shc/ShcA exists as three isoforms, of 66, 52 and 46 kDa, respec-
tively. As all members of the Shc family, the three ShcA isoforms
consist of a central proline-rich collagen homology (CH1) domain
ﬂanked by a N-terminal PTB domain and a C-terminal SH2 domain.
p66Shc is endowed of an additional collagen homology domain
(CH2) at the N-terminus. Due to alternative promoter usage,
p52Shc/p46Shc are constitutively expressed at high levels in all tis-
sues, with the exception of mature neuronal cells, while expression
of p66Shc is tissue-restricted. Compared to the other two isoforms,
T and B cells express modest levels of p66Shc, which however in-
crease when cells are treated with apoptogenic stimuli. The CH1
domain contains three tyrosine residues (YY239/240, Y317) which,
when phosphorylated, become docking sites for Grb2 or other SH2
domain-containing proteins, while the CH2 domain contains a
phosphorylatable serine residue (S36) [29].
As opposed to p52Shc, which couples a number of receptors,
including antigen receptors, to Ras activation by recruiting Grb2/
Sos (Son of Sevenless) close to Ras at the plasma membrane,
p66Shc effectively dampens both TCR and BCR signaling, as shown
by the hyperreactivity to antigen receptor engagement of periphe-
ral T and B cells from p66Shc/ mice both in vitro and in vivo. A
higher proportion of p66Shc/ lymphocytes acquires indeed acti-
vation markers in response to antigen receptor engagement com-pared to their wild-type counterparts. p66Shc/ T and B cells
also display a more robust proliferative response when stimulated
in vitro. Moreover both delayed type hypersensitivity, a process
crucially dependent on T cells, and antibody responses to a T-
dependent antigen, are enhanced in p66Shc/ mice. Consistent
with these alterations, TCR and BCR signaling is enhanced in the
absence of p66Shc [30].p66Shc has been shown to competitively
inhibit p52Shc recruitment to the activated EGF (Epidermal Grow-
th Factor) receptor in ﬁbroblasts. We have demonstrated that this
also occurs in T cells, where p66Shc interacts with the TCR even in
the absence of stimulation, which may account for the ability to
compete with p52Shc notwithstanding its relatively low expres-
sion. Following phosphorylation on the tyrosine residues in the
CH1 domain, p66Shc recruits Grb2/Sos complexes in a non-produc-
tive interaction. Hence p66Shc not only antagonizes p52Shc
recruitment to the activated receptor but also limits the availabil-
ity of its effectors, thereby suppressing Ras activation [31]. Inter-
estingly, the enhancement in BCR signaling in B cells from
p66Shc/ mice is not limited to Erk, as expected from the known
inhibitory activity of p66Shc on Ras activation, but extends to other
signaling mediators, beginning from Syk [32]. This implies that,
similar to other adaptors with negative regulatory function, the
range of p66Shc targets might be wider than predicted from its
known mechanism of action.
In addition to their hyperreactivity to antigen receptor trigger-
ing, p66Shc/ lymphocytes are more long-lived than their wild-
type counterparts when cultured ex vivo, and are moreover more
resistant to proapoptotic stimuli, including prolonged antigen
receptor cross-linking [30]. This can be accounted for, at least in
part, by the enhanced activation of Akt downstream of both the
TCR and the BCR [32]. Akt is a key participant in a survival pathway
initiated by PI-3K activation which culminates in an alteration in
the ﬁne balance of proapoptotic and antiapoptotic proteins on
which cell commitment to survival or death crucially depends.
Among these, the Bcl-2 (B-cell lymphoma 2) family plays a major
role [33]. We have demonstrated that expression of both proapop-
totic and antiapoptotic Bcl-2 family members is altered in
p66Shc/ peripheral B cells, with results in tilting the balance to-
wards survival [32], indicating that survival signaling by the BCR is
ﬁne-tuned by p66Shc by modulating the expression of Bcl-2
proteins through attenuation of the PI-3K/Akt pathway. The pro-
survival function of Erk, which is enhanced in p66Shc/ B cells,
is also likely to contribute to their enhanced resistance to
apoptosis.
In addition to its adapter-related role in dampening antigen
receptor signaling, p66Shc has the ability to increase the levels of
reactive oxygen species (ROS), thereby promoting cell apoptosis
in response to stress. This unexpected activity, ﬁrst identiﬁed in
embryonic ﬁbroblasts from p66Shc/ mice, has been ascribed to
two different mechanisms which likely work in concert. First,
p66Shc enhances both homeostatic and acute ROS production by
shutting off the expression of enzymes involved in oxidant scav-
enging (e.g. catalase). This involves triggering the exit from the nu-
cleus of the transcriptional factor FOXO1. Second, p66Shc has an
intrinsic ROS-generating activity resulting from its capacity to
interrupt the respiratory chain in mitochondria. This triggers open-
ing of the permeability transition pore in the outer mitochondrial
membrane, resulting in dissipation of the transmembrane poten-
tial and cytochrome-c release, which activates the caspase cascade
[29]. We have demonstrated that in T cells p66Shc promotes apop-
tosis in response to a number of apoptogenic stimuli not only by
targeting mitochondria, but also by altering Ca2+ homeostasis
through its ROS-elevating activity [34]. Both the capacity to dam-
pen the PI-3K/Akt survival pathway and its direct proapoptotic
activity of p66Shc are likely to account for the extended survival
of p66Shc/ lymphocytes.
Fig. 1. Negative regulation of TCR and BCR signaling by p66Shc and Rai. (A) p66Shc and Rai uncouple the TCR from Ras and ZAP-70 activation, respectively, leading to
impaired activation of downstream mediators (Erk, Akt) essential for T cell activation and survival. p66Shc further negatively impinges on cell survival by (i) impairing
mitochondrial integrity through modulation of the expression of pro- and anti-apoptotic members of the Bcl-2 family; (ii) by impairing Ca2+ homeostasis through a ROS-
dependent pathway which affects Ca2+ extrusion by targeting plasma membrane ATPases. (B) p66Shc and Rai uncouple the BCR from Syk activation, leading to impaired
activation of Erk and Akt. This results in defective B cell activation and impaired survival. The capacity of p66Shc to profoundly affect the Bcl-2 family balance underlies to a
signiﬁcant extent its negative effects on B cell survival. Consistent with the role of p66Shc and Rai as negative regulators of TCR and BCR signaling, p66Shc/ and Rai/mice
develop a lupus-like autoimmune disease. (C) Neoplastic B cells from CLL patients share a defect in p66Shc expression, which is causally implicated in the bias in the Bcl-2
family towards the antiapoptotic members and the extended B cell survival characteristic of this disease.
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Compared to ShcA, expression of ShcC/Rai is more restricted
and developmentally regulated, with the highest expression in
post-mitotic neurons, where it is found as two isoforms of 64
and 52-kDa. Rai shares the same domain organization as ShcA,
with a N-terminal PTB and a C-terminal SH2 domain spaced by aCH1 domain which is phosphorylated on residues YY221/222 and
Y304 following recruitment to the cytosolic tail of a number of
growth factor receptors (e.g. Ret, TrkB). Rai couples the activated
receptors to the PI-3K/Akt/Bad (Bcl-2-associated death promoter)
signaling pathway, thereby promoting neuronal survival [29].
Although Rai expression appears principally restricted to differen-
tiated neurons in the central nervous system, small amounts of
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enteric glial cells, endothelial cells and smooth muscle cells and,
more recently, in both T and B lymphocytes [35].
Surprisingly, peripheral T and B cells from Rai/ mice were
found to survive longer when cultured ex vivo in conditions of ser-
um deprivation, and are moreover more resistant to apoptosis in-
duced by prolonged antigen receptor ligation, indicating that, as
opposed to neuronal cells, Rai does not promote lymphocyte sur-
vival, but conversely antagonizes this process. Akt phosphorylation
in these cells is strongly upregulated in response to TCR or BCR
engagement, to levels signiﬁcantly higher that in wild-type lym-
phocytes, indicating that Rai controls lymphocyte survival by mod-
ulating the extent of activation of the PI-3K/Akt pathway, similar to
neuronal cells, but in the opposite direction. The dampening func-
tion of Rai on TCR and BCR signaling is not restricted to the PI-3K
pathway, as Erk activation and Ca2+ mobilization are also enhanced
in Rai/ lymphocytes. This wide range of targets is accounted for
by the fact that Rai uncouples the TCR and BCR from the activation
of the initiating kinases, ZAP-70 and Syk respectively, as shown by
the enhanced response to antigen receptor engagement of Rai/
lymphocytes. Consistent with these observations, Rai/ T and B
lymphocytes are hyperresponsive to antigen receptor engagement
compared to their wild-type counterparts. Proliferative responses
to TCR and BCR agonists are also enhanced, as is the in vivo hap-
ten-speciﬁc T cell response, underscoring the role of Rai as a neg-
ative regulator of TCR and BCR signaling [35].
The mechanism whereby Rai interferes with antigen receptor
signaling is as yet unknown. Although Rai can interact with Grb2
through the phosphorylated CH1 domain, the afﬁnity for Grb2 is
signiﬁcantly lower compared to p52Shc, suggesting that, similar
to p66Shc, Rai may transdominantly inhibit Ras activation by
p52Shc. This does however not account for the inhibitory activity
of Rai on antigen receptor-dependent ZAP-70 and Syk phosphory-
lation. In a Jurkat T cell overexpression model we found that Rai
interacts with phosphorylated CD3f in response to TCR ligation,
and that under these conditions the interaction of ZAP-70 with
CD3f, as well as its activation, are impaired (Ferro et al., manu-
script in preparation), suggesting that Rai may prevent activation
of Syk kinases by interfering with their recruitment to the antigen
receptors.
3.3. p66Shc and Rai deﬁciency in disease
p66Shc/ and Rai/ mice develop splenomegaly, character-
ized by white pulp hyperplasia and the presence of germinal cen-
ters, indicative of spontaneous lymphocyte activation. Activated
T- and B cells are indeed found with signiﬁcantly higher frequency
in the spleen and lymph nodes of these mice compared to controls
[30,35]. The hyperreactivity of p66Shc/ and Rai/ lymphocytes
to signals triggered by the antigen receptor suggests that loss of
the inhibitory activity of these adaptors on TCR and BCR signaling
may facilitate the activation, proliferation and survival of the rare
peripheral self-reactive lymphocytes that have escaped negative
selection, leading to accumulation of self-reactive lymphocytes in
the periphery. Consistent with this notion, p66Shc/ and Rai/
mice develop a lupus-like autoimmune disease, characterized by
circulating anti-dsDNA, increased frequencies of peritoneal B-1
cells, glomerular deposition of immune complexes and proteinuria.
Some pathological features are however unique. Speciﬁcally, the
glomerular alterations are very different, with thickening of the
basement membrane and effacement of foot processes in
p66Shc/mice, and formation of crescent-like structures of amor-
phous proteinaceous material in Bowman’s space, with resulting
collapse of the glomerular tuft, in Rai/ mice [30,35]. Moreover
a signiﬁcant proportion of p66Shc/ mice, but not Rai/ mice,
display alopecia, which affects preferentially females and is associ-ated with immune destruction of hair follicles. Immune complexes
are found diffusely deposited in the subcutaneous layer of these
mice, suggesting the existence of autoantibodies against a local
component [30]. These differences in the pathological features ob-
served in Rai/ and p66Shc/ mice suggest that, while both
implicated in the attenuation of the signals emanated from the
TCR and BCR, Rai and p66Shc are not redundant. These ﬁndings
provide in vivo evidence of the role of p66Shc and Rai as negative
regulators of antigen receptor signaling and autoimmunity. The
study of SLE patients is expected to shed light into the potential
contribution of these adapters to autoimmunity in humans.
We have recently translated our ﬁndings to the pathological
context of B cell chronic lymphocytic leukemia (CLL), a malignancy
characterized by progressive accumulation of monoclonal CD5+ B
cells in peripheral blood, bone marrow and peripheral lymphoid
organs [36]. These cells are arrested in the G0/G1 phase of the cell
cycle and accumulate in tissues due to prolonged survival. Intrinsic
defects in a number of components of the apoptotic circuitry have
been identiﬁed in CLL B cells. Among these, alterations in the
expression of anti- and proapoptotic members of the Bcl-2 family
are among the most common features [37]. Our ﬁnding that
peripheral B cells from p66Shc/ mice display an alteration in
the balance of Bcl-2 related genes compared to wild-type controls
prompted us to investigate the potential link between p66Shc and
CLL. We found that p66Shc expression was profoundly impaired in
CLL B cells compared to peripheral B cells from healthy donors,
with the lowest levels in patients with poor prognosis, based on
the mutational status of the IgH variable region genes. Reconstitu-
tion of p66Shc expression in CLL B cells restored the balance
among Bcl-2 family members, with a decrease in expression of
the antiapoptotic members Bcl-2 and Bcl-xL and an increase in
expression of the proapoptotic members Bax (Bcl-2-associated X
protein) and Bak (Bcl-2 homologous antagonist/killer) [32]. Since
Akt has the ability to promote Bcl-2, Bcl-xL and Mcl-1 expression
in both normal and leukemic B cells, the enhanced activation of
Akt in response to BCR engagement both in p66Shc/ B cells
and in CLL B cells is likely to underlie at least in part the altered
balance in the Bcl-2 family. Moreover, Bax and Bcl-2 expression
can be inversely modulated by the redox state of the cell [38], sug-
gesting that p66Shc may alter the expression of Bcl-2 family mem-
bers through its ROS-elevating activity. The capacity of p66Shc to
tilt the Bcl-2 family balance towards apoptosis is likely to play a
signiﬁcant role in the extended survival of CLL B cells. Of note, B
cells from patients with poor prognosis are not only long-lived
but, at variance with neoplastic B cells from patients with stable
disease, are also able to actively respond to BCR engagement
[36]. The enhancement in BCR signaling due to the drop of
p66Shc expression below a critical threshold in these patients
may favour not only survival, but also growth of the malignant
cells, thereby contributing to disease aggressiveness.4. Future perspectives
Mice genetically manipulated to lack or express speciﬁc mu-
tants of adapters identiﬁed as negative regulators of antigen recep-
tor signaling in cell models have provided important – and in some
instances unexpected – insight into their function. First, the lack of
the expected defects in mice lacking speciﬁc adaptors, such as PAG
or TRIM, indicates that, as opposed to the clear-cut results obtained
in cell models, a number of adaptors may be functionally redun-
dant. This is not surprising, considering the importance of these
adaptors in contributing to setting the threshold for productive
signaling, which is essential for keeping at bay unwanted immune
responses. On the other hand, it cannot be excluded that
these apparently redundant adapters may actually play a role in
4922 N. Capitani et al. / FEBS Letters 584 (2010) 4915–4922controlling inﬂammatory responses in the context of infectious
disease, an issue which deserves investigation. It should be under-
scored that, in the instances where autoimmunity develops, the
pathological features are very similar, generally classifying as
systemic lupus-like disease, characterized by the presence of circu-
lating autoantibodies against nuclear components and glomerulo-
nephritis associated with glomerular deposition of immune
complexes. The relative abundance of nuclear antigens released
from apoptotic cells compared to tissue-speciﬁc antigens may
account for the fact that, unless disease is triggered by exogenous
administration of self-antigen that will promote organ-speciﬁc
damage (e.g. myelin peptides to induce EAE), autoimmunity in
these mice is invariably systemic. Second, notwithstanding the
wide array of interactions identiﬁed in cell models, which for some
adapters would suggest a function as both positive and negative
regulator of antigen receptor signaling, only a discrete number of
these interactions is relevant in vivo, such that one function is
unambiguously dominant (e.g. NTAL). Third, although in a number
of mice lacking adaptors with a negative regulatory function lym-
phocytes are hyperreactive to antigen receptor engagement, the
defect appears to affect the signaling cascade more upstream than
expected from the data generated in cell models (e.g. Dok-1/2,
p66Shc), which results in a more generalized defect, indicating
that the precise mechanism whereby these adaptors attenuate
signaling has yet to be fully clariﬁed. Nevertheless, the auto-
immune disease developed by some of these mice (e.g. NTAL/,
Dok-1/Dok-2/, p66Shc/, Rai/) supports the notion that
negative regulators of antigen receptor signaling may provide a
valid handle to our understanding of autoimmunity and lympho-
proliferative disease, as exempliﬁed by the ﬁnding of the defect
in p66Shc expression in CLL patients. Negative adaptors have thus
the potential to become a novel class of therapeutic targets for the
development of speciﬁc treatments for diseases characterized by
uncontrolled antigen receptor signaling.
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